Alphabet's Stock Ranks 23rd in U.S. Trading Activity on 31.7% Volume Drop

Generated by AI AgentAinvest Volume Radar
Friday, Sep 12, 2025 8:19 pm ET1min read
GOOGL--
Aime RobotAime Summary

- Alphabet's stock rose 0.25% on Sept 12, 2025, with $3.49B volume, a 31.72% drop from prior day, ranking 23rd in U.S. trading activity.

- DeepMind's Isomorphic Labs, led by Demis Hassabis, partners with Eli Lilly/Novartis to use AI for drug discovery, aiming to cut development timelines from years to months.

- Verily faces federal lawsuit over alleged HIPAA violations, claiming improper use of 25,000+ patients' health data in diabetes program (2017-2021), now in San Francisco court.

- Alphabet's "Other Bets" unit shifts focus to AI after medical device program cuts, while Isomorphic Labs has raised $600M targeting cancer/immune disorders.

Alphabet Inc. (GOOGL) closed on September 12, 2025, , , . The stock ranked 23rd in trading activity among U.S. equities. Meanwhile, the company’s DeepMind division, led by Nobel laureate , highlighted advancements in AI-driven drug discovery. Isomorphic Labs, a DeepMind subsidiary, aims to reduce drug development timelines from years to months by leveraging artificial intelligence. The unit, which has partnered with Eli LillyLLY-- and NovartisNVS--, . Despite no AI-developed medicine yet passing clinical trials, Hassabis anticipates significant progress within the next few years.

A separate legal challenge emerged as a former executive at Alphabet’s Verily subsidiary filed a lawsuit alleging repeated violations of federal patient privacy laws. The lawsuit claims Verily improperly used protected health information from over 25,000 patients in its diabetes program between 2017 and 2021. The case, now in federal court in San Francisco, involves allegations that the company concealed breaches of HIPAA agreements. Verily, part of Alphabet’s “Other Bets” portfolio, has shifted focus toward AI in recent months after announcing cuts to its medical device program.

To make sure I set up the back-test exactly the way you expect, could you please confirm a couple of details? 1. Market universe • Are we talking about all U.S. listed common stocks (NYSE + NASDAQ), or a different universe? 2. Execution price • Should the positions be opened at the next day’s open (after yesterday’s volume ranking) and closed at that day’s close, or do you prefer another convention (e.g., buy today’s close, sell tomorrow’s close)? 3. Rebalancing cost assumptions • Do you want me to include any transaction cost or slippage for entering/exiting 500 names every day? • If yes, what cost per trade (in basis points) should I assume? Once I have these details I can generate the ranking each day, create the daily one-day-holding signals, and run the back-test from 2022-01-01 to the latest available date.

Hunt down the stocks with explosive trading volume.

Latest Articles

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet